26.52
4.98%
-1.39
시간 외 거래:
27.41
0.89
+3.36%
전일 마감가:
$27.91
열려 있는:
$28
하루 거래량:
690.29K
시가총액:
$714.13M
수익:
$157.75M
순이익/손실:
$-29.73M
주가수익비율:
8.8696
EPS:
2.99
순현금흐름:
$-21.00M
1주 성능:
+1.34%
1개월 성능:
-17.69%
6개월 성능:
+42.50%
1년 성능:
+4.82%
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
명칭
Arcturus Therapeutics Holdings Inc
전화
858-900-2660
주소
10628 Science Center Drive, Suite 250, San Diego, CA
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-07-24 | 개시 | William Blair | Outperform |
2023-05-11 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2022-11-14 | 재개 | Wells Fargo | Overweight |
2022-11-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
2022-11-03 | 업그레이드 | Citigroup | Neutral → Buy |
2022-11-02 | 업그레이드 | Barclays | Underweight → Equal Weight |
2022-08-10 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
2022-07-19 | 재개 | Cantor Fitzgerald | Overweight |
2022-05-11 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
2022-04-21 | 다운그레이드 | Citigroup | Buy → Neutral |
2022-01-31 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
2021-08-12 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
2021-08-11 | 다운그레이드 | Goldman | Neutral → Sell |
2021-08-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
2021-07-02 | 개시 | Cantor Fitzgerald | Overweight |
2021-06-25 | 재개 | Goldman | Neutral |
2021-06-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
2021-06-04 | 재개 | Robert W. Baird | Neutral |
2021-02-17 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
2021-01-19 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
2021-01-15 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
2021-01-07 | 개시 | Wells Fargo | Overweight |
2020-12-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2020-12-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2020-12-29 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2020-12-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
2020-12-23 | 다운그레이드 | ROTH Capital | Buy → Sell |
2020-12-08 | 재확인 | B. Riley Securities | Buy |
2020-12-07 | 재확인 | B. Riley Securities | Buy |
2020-10-26 | 개시 | Barclays | Overweight |
2020-10-06 | 개시 | Citigroup | Buy |
2020-08-26 | 개시 | Piper Sandler | Overweight |
2020-07-30 | 재개 | ROTH Capital | Buy |
2020-07-16 | 개시 | Raymond James | Outperform |
2020-07-13 | 개시 | B. Riley FBR | Buy |
2020-06-09 | 다운그레이드 | WBB Securities | Buy → Hold |
2020-02-11 | 개시 | Robert W. Baird | Outperform |
2020-02-07 | 개시 | Guggenheim | Buy |
2020-02-06 | 개시 | Guggenheim | Buy |
2019-04-05 | 개시 | H.C. Wainwright | Buy |
2018-09-20 | 업그레이드 | WBB Securities | Buy → Strong Buy |
2018-01-22 | 개시 | Chardan Capital Markets | Buy |
모두보기
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Investment Research
Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
Benzinga
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
Zacks Investment Research
Logitech Posts Q3 Results, Joins Coinbase And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga
Arcturus Therapeutics Holdings Inc (ARCT) 재무 분석
Arcturus Therapeutics Holdings Inc (ARCT) 매출 2024
ARCT은 2023-12-31 종료 분기에 대해 매출(지난 12개월)이 157.75M 달러로 보고했으며, 전년대비 -23.33% 감소했습니다.
Arcturus Therapeutics Holdings Inc (ARCT) 순이익 2024
ARCT은 2023-12-31 종료 분기에 대해 순이익(지난 12개월)이 -29.73M 달러로 보고했으며, 전년대비 -417.95% 감소했습니다.
Arcturus Therapeutics Holdings Inc (ARCT) 현금흐름 2024
2023-12-31 종료 분기에 ARCT은 현금흐름(지난 12개월)으로 -21.00M 달러를 기록했으며, 전년 대비 -186.54% 감소했습니다.
Arcturus Therapeutics Holdings Inc (ARCT) 주당 순이익 2024
ARCT이 보고한 2023-12-31 종료 분기의 주당 순이익(지난 12개월)은 -1.16달러이며, 전년 대비 -441.18% 감소했습니다.
Arcturus Therapeutics Holdings Inc 주식 (ARCT) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Chivukula Pad | Chief Scientific Officer & COO |
Mar 19 '24 |
Sale |
35.01 |
8,565 |
299,839 |
490,883 |
Chivukula Pad | Chief Scientific Officer & COO |
Nov 01 '23 |
Sale |
18.72 |
5,000 |
93,602 |
499,448 |
Chivukula Pad | Chief Scientific Officer & COO |
Oct 02 '23 |
Sale |
25.61 |
5,000 |
128,062 |
504,448 |
Chivukula Pad | Chief Scientific Officer & COO |
Sep 01 '23 |
Sale |
31.45 |
5,000 |
157,264 |
509,448 |
Chivukula Pad | Chief Scientific Officer & COO |
Aug 01 '23 |
Sale |
34.91 |
5,000 |
174,550 |
514,448 |
Kummerfeld Keith C | See Remarks |
Jul 14 '23 |
Option Exercise |
8.96 |
6,968 |
62,408 |
7,918 |
Chivukula Pad | Chief Scientific Officer & COO |
Jul 14 '23 |
Sale |
35.01 |
25,000 |
875,250 |
519,448 |
Kummerfeld Keith C | See Remarks |
Jul 14 '23 |
Sale |
35.00 |
6,968 |
243,880 |
950 |
Chivukula Pad | Chief Scientific Officer & COO |
Jul 03 '23 |
Sale |
28.75 |
5,000 |
143,750 |
544,448 |
Chivukula Pad | Chief Scientific Officer & COO |
Jun 01 '23 |
Sale |
27.16 |
5,000 |
135,800 |
549,448 |
자본화:
|
볼륨(24시간):